单位：万元 非经营性资金占用 资金占用 方名称 占用方与上 市公司的关 联关系 上市公司 核算的会 计科目 2025 年期初 占用资金余额 2025年半年度占 用累计发生金额 （不含利息） 2025 年半年度 占用资金的利 息（如有） 2025 年半年度 偿还累计发生 金额 2025 年半年度 期末占用资金 余额 占用形 成原因 占用性质 控股股东、实际控制人及 其附属企业 无 不适用 不适用 - - - - - 不适用 不适用 前控股股东、实际控制人 及其附属企业 无 不适用 不适用 - - - - - 不适用 不适用 其他关联方及附属企业 无 不适用 不适用 - - - - - 不适用 不适用 总计 - - - - - 其它关联资金往来 资金往来 方名称 往来方与上 市公司的关 联关系 上市公司 核算的会 计科目 2025 年期初 往来资金余额 2025年半年度往 来累计发生金额 （不含利息） 2025 年半年度 往来资金的利 息（如有） 2025 年半年度 偿还累计发生 金额 2025 年半年度 期末往来资金 余额 往来形 成原因 往来性质 （经营性往来、 非经营性往来） 控股股东、实际控制人及 其附属 ...

每经AI快讯，8月27日，迈瑞医疗(300760.SZ)公告称，公司2025年上半年实现营业收入167.43亿元，同 比下降18.45%；归属于上市公司股东的净利润为50.69亿元，同比下降32.96%；公司拟向全体股东每10 股派发现金红利13.10元（含税）。 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-030 深圳迈瑞生物医疗电子股份有限公司 第八届董事会第十三次会议决议公告 经审议，董事会认为公司严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》《上市公司募集资金监管规则》《深圳证券交易所上市公司自律 监管指引第2号——创业板上市公司规范运作》等法律、法规、规范性文件以及公司《募集 资金管理办法》等的规定使用募集资金，并及时、真实、准确、完整履行相关信息披露工 作，公司募集资金的实际使用合法、合规，未发现违反法律法规及损害股东利益的行为， 不存在违规使用募集资金的情形。 本议案已经公司董事会审计委员会审议通过。 具体内容详见公司同日刊载于巨潮资讯网（www.cninfo.com.cn）上的相关公告。 表决结果：同意票11票、反对票0票、弃权票0票。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）第八届董事会第十三次会议 于2025年8月27日10:30在公司会议室以现场结合通讯方式 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-032 深圳迈瑞生物医疗电子股份有限公司 关于2025年第二次中期利润分配方案公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、审议程序 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于2025年8月27日召开第八 届董事会第十三次会议，审议通过了《关于2025年第二次中期利润分配方案的议案》。本 次利润分配方案在公司2024年年度股东大会决议授权范围内，经公司董事会审议通过后， 无需再次提交股东会审议。 二、利润分配方案的基本情况 为积极响应监管号召、提高股东回报，公司推动一年多次分红，结合监管规则，以2024 年经审计的未分配利润为基准，合理考虑当期利润情况实施中期分红。根据《中华人民共 和国公司法》（以下简称"《公司法》"）和《深圳迈瑞生物医疗电子股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，当法定盈余公积金累计额达到股本的50%以上时不再 提取。截至2018年12月31日公司法定盈余公积为607,845,633.00元，达到股本总额的50%， 其后至2025年半 ...

深圳迈瑞生物医疗电子股份有限公司 2025 年半年度报告全文 深圳迈瑞生物医疗电子股份有限公司 2025 年半年度报告 2025 年 08 月 1 深圳迈瑞生物医疗电子股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人李西廷、主管会计工作负责人吴昊及会计机构负责人（会计 主管人员）赵云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的未来发展规划等前瞻性陈述不构成公司对投资者的实质 承诺，敬请广大投资者理性投资，注意风险。 公司在本半年度报告中详细阐述了未来可能发生的有关风险因素及对策， 详见"第三节 管理层讨论与分析"之"十、公司面临的风险和应对措施"， 敬请投资者予以关注。 公司经本次董事会审议通过的利润分配预案为：以公司 2025 年 6 月 30 日的总股本 1,212,441,394 股为基数，向全体股东每 10 股派发现金红利 13.10 元（含税），送红股 0 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [1][5]. Core Insights - The report highlights the upcoming World Lung Cancer Conference (WCLC) where Chinese pharmaceutical companies will present innovative research results, particularly focusing on domestic innovative drug companies [2][11]. - The pharmaceutical sector has shown weaker performance compared to the overall market, with a current price-to-earnings ratio (TTM) of 40.45x, which is at the 83.46th percentile of the historical valuation over the past five years [1][2]. Company-Specific Summaries - **Mindray Medical (300760.SZ)**: Rated "Outperform" with a projected net profit of 11.67 billion in 2024, increasing to 16.19 billion by 2027, and a PE ratio decreasing from 25.4 in 2024 to 18.3 in 2027 [4]. - **Aier Eye Hospital (300015.SZ)**: Rated "Outperform" with a projected net profit of 3.56 billion in 2024, increasing to 5.76 billion by 2027, and a PE ratio decreasing from 35.1 in 2024 to 21.7 in 2027 [4]. - **WuXi AppTec (603259.SH)**: Rated "Outperform" with a projected net profit of 9.35 billion in 2024, increasing to 14.51 billion by 2027, and a PE ratio decreasing from 29.7 in 2024 to 19.2 in 2027 [4]. - **Innovent Biologics (9926.HK)**: Rated "Outperform" with a projected net profit of -0.51 billion in 2024, turning positive to 1.79 billion by 2027, with a PE ratio from -281.7 in 2024 to 80.8 in 2027 [4]. - **Legend Biotech (688212.SH)**: Rated "Outperform" with a projected net profit of 0.2 million in 2024, increasing to 1.2 million by 2027, and a PE ratio decreasing from 321.8 in 2024 to 54.5 in 2027 [4]. Market Performance - The overall A-share market increased by 3.58%, with the Shanghai Composite Index rising by 4.18%, while the biotechnology sector only saw a 1.05% increase, indicating underperformance relative to the broader market [1][2].

Core Viewpoint - The A-share market is experiencing a surge in sentiment, with the Shanghai Composite Index surpassing 3800 points and the ChiNext Index rising over 30% in the past three months, reaching a three-year high [1][3]. Group 1: Market Performance - The ChiNext ETF (159915) has attracted significant capital, with an increase of approximately 15 billion yuan in scale this month, bringing its total scale to over 100 billion yuan as of August 25 [1]. - The ChiNext has a total market capitalization exceeding 16 trillion yuan, with over 1380 listed companies as of August 25 [1][3]. Group 2: Innovation and R&D - The average annual growth rate of R&D expenditure for ChiNext companies from 2020 to 2024 is 16.3%, leading among A-share sectors [3]. - ChiNext companies have achieved notable global market shares in various sectors, including nearly 40% in power batteries and being the largest global supplier of photovoltaic inverters [3]. Group 3: Index Characteristics - The ChiNext Index, ChiNext 50 Index, and ChiNext 200 Index are based on different selection criteria, focusing on large-cap, mid-cap, and a broader range of stocks, respectively [5][6]. - The ChiNext Index and ChiNext 50 Index have a higher concentration of large-cap stocks, with over 50% of their weight in companies with market capitalizations exceeding 100 billion yuan [7][14]. - The industry distribution of the indices shows a strong focus on emerging industries, with the ChiNext Index and ChiNext 50 Index heavily weighted in industrial, information technology, and telecommunications sectors [10][12]. Group 4: Investment Opportunities - The three ChiNext indices exhibit strong growth potential and volatility, making them suitable for investors with varying risk appetites [14]. - E Fund has established a presence in the ChiNext market with its ETFs tracking the ChiNext Index, ChiNext 50 Index, and ChiNext 200 Index, all with a management fee of 0.15% per year [14].

Core Insights - The biopharmaceutical industry in Shenzhen is rapidly emerging as a significant hub, transitioning from a manufacturing base to a center for innovative drugs and high-end medical devices, with an industrial output value of 49.922 billion yuan in 2022 [1][4][6]. Industry Overview - As of 2024, Shenzhen has 2,780 biopharmaceutical companies, including 2,468 medical device firms, 133 health product companies, and 114 chemical drug manufacturers [1]. - Shenzhen is recognized not only as a "world factory" but also as an "innovation workshop," producing several self-developed innovative treatment products and housing global medical device giants like Mindray Medical and leading biotech firms like BGI [4][6]. Policy and Strategic Support - The "20+8" industrial cluster strategy has been pivotal in guiding the development of strategic emerging industries, including biopharmaceuticals, providing support in funding, talent, and land [7][8]. - Shenzhen's government has played a crucial role in fostering an innovative ecosystem, facilitating the growth of high-tech enterprises through coordinated support and resources [7]. Spatial Development - Shenzhen's biopharmaceutical industry has formed a new pattern of "one core and multiple centers," focusing on technological innovation, industrial transformation, and manufacturing [8][10]. - Key areas for research and production are concentrated in Pingshan, while other districts like Nanshan and Futian focus on research and design [10]. Healthcare System Integration - Shenzhen's unique community health service system, comprising 975 health service institutions, enhances the accessibility and affordability of medical services, supporting the biopharmaceutical industry's growth [11][13]. - The integration of AI in healthcare is advancing rapidly, with 13 medical AI application scenarios being implemented, optimizing patient care processes and providing opportunities for collaboration with biopharmaceutical companies [11][14]. Future Prospects - The biopharmaceutical industry in Shenzhen is poised for further growth, leveraging advancements in AI, big data, and personalized health management to explore new paradigms in smart healthcare [14].

Core Viewpoint - The article discusses the performance of the Science and Technology Innovation ETF (588360), highlighting its recent market movements and key holdings [1]. Group 1: ETF Performance - The Science and Technology Innovation ETF (588360) opened down 0.84%, priced at 0.826 yuan [1]. - Since its inception on June 29, 2021, the ETF has returned -17.06%, while its return over the past month has been 25.11% [1]. Group 2: Key Holdings - Major holdings in the ETF include: - Ningde Times down 1.12% - SMIC down 2.10% - Mindray down 0.57% - Haiguang Information down 3.29% - Zhongji Xuchuang down 2.00% - Xinyi Sheng up 0.63% - Cambrian down 5.41% - Huichuan Technology up 0.21% - Sunshine Power down 0.66% - Lanke Technology down 0.96% [1].

Core Viewpoint - The double innovation ETF (588300) opened with a decline of 1.01%, indicating a negative market sentiment towards the fund and its underlying assets [1] Group 1: ETF Performance - The double innovation ETF (588300) opened at 0.782 yuan, reflecting a decrease of 1.01% [1] - Since its establishment on June 25, 2021, the fund has recorded a return of -21.15% [1] - Over the past month, the fund has shown a recovery with a return of 25.13% [1] Group 2: Major Holdings Performance - Major holdings in the ETF include: - Ningde Times: down 1.12% [1] - SMIC: down 2.10% [1] - Mindray: down 0.57% [1] - Haiguang Information: down 3.29% [1] - Zhongji Xuchuang: down 2.00% [1] - Xinyi Sheng: up 0.63% [1] - Cambrian: down 5.41% [1] - Huichuan Technology: up 0.21% [1] - Sunshine Power: down 0.66% [1] - Lanke Technology: down 0.96% [1]